fbpx

Alzamend Neuro™ Announces Appointment of Dr. Eric McDade to Its Scientific Advisory Board

26 Views

Company Selects Innovative Researcher and Leader, Associate Director of DIAN-TU


TAMPA, Fla.–(BUSINESS WIRE)–#Alzamend–Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it had appointed Eric McDade, DO, a board-certified cognitive neurologist, as its next member to its Scientific Advisory Board. Dr. McDade, an innovative researcher and leader since 2010, has focused his activities on the evaluation of those with dementia syndromes and on developing a clinical research program that focuses on using brain imaging and cerebrospinal fluid markers to identify those at risk for Alzheimer disease (“AD”). Currently, Dr. McDade is leveraging his clinical expertise to develop a cross-disciplinary team that combines neuroimaging, clinical evaluations and basic science to better explore and translate work in the use of imaging and fluid biomarkers to better understand the timing and relationship between measures of disease risk and progression. The goal of this work is to identify better measures and target for interventions and prevention for Alzheimer’s disease and has led to over 76 peer-reviewed publications and continuous funding from the NIH for over 5 years.

Dr. McDade is the Associate Director of the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU). The DIAN-TU is a global network of families at risk for a genetic form of AD and is pioneering prevention trials for this young-onset form of AD. As part of this he serves as the Principle Investigator of the DIAN-TU Primary Prevention Study. He is also the Director of the DIAN Expanded Registry (DIAN EXR). The DIAN EXR is an international research registry for individuals with confirmed or suspected dominantly inherited Alzheimer’s disease (DIAD) in their families and for professionals and researchers involved in clinical care and research on DIAD. These projects will prove critical to advancing the field of Alzheimer disease treatment.

Alzamend™ is very pleased having Dr. McDade join the Company’s Scientific Advisory Board and believes he will greatly assist the Company’s CEO, Stephan Jackman, to navigate the scientific and regulatory challenges commonly faced by a developmental biotech company as it pursues the commercialization of its two patented therapeutic solutions for Alzheimer’s disease. “We believe Dr. McDade’s appointment as a member of our Scientific Advisory Board is a great addition and selection given his unique experience and leadership working with the DIAN project, a global program to prevent Alzheimer’s disease. We look forward to his guidance and expertise as the Company pursues a more vigorous agenda to advance LiProSal™ and CAO22W for the remainder of 2019 and beyond,” stated Mr. Jackman.

Dr. McDade has received several awards and honors in recognition of his work and leadership including the NIH-NIA K23 Training Grant Award and a NIH-NIA UO1 award for the DIAN-TU Primary Prevention Trial. Additionally, he has been a LRP Recipient and received the Excellence in Clinical Teaching Award and has been on the Best Doctors in St. Louis and in Pittsburgh lists.

Dr. McDade earned his doctorate at Chicago College of Osteopathic Medicine and a B.A. in Psychology from Canisius College. Dr. McDade completed an internship at the University of Illinois College of Medicine in Chicago and his residency at the University of Maryland where he was a Chief Resident. Dr. McDade has his certification of Neurology from the American Board of Psychiatry and Neurology and Behavioral Neurology from the United Council of Neurologic Subspecialties.

Dr. McDade stated, “I am excited to work with Alzamend’s™ management team as a member of its Scientific Advisory Board so I can apply my experience and knowledge as a researcher, team member and project leader to help move the Company’s patented solutions through the clinical trial process and into market to help those suffering with Alzheimer’s disease.”

In the U.S., Alzheimer’s disease is the most prevalent form of dementia, estimated to effect over 5.8 million adults today. The company’s goal is to move two therapeutic technologies out of the research and preclinical testing stages into clinical trials as it works toward commercialization. It is projected that by the year 2050, one in three seniors will have AD or another form of dementia and the disease may affect as many as 88 million adults if a cure is not found. Alzheimer’s disease is one of the costliest chronic diseases in the United States and the 2019 economic impact to society was $293 billion.

The Company recommends its shareholders and any interested parties read its public reports and financial statements filed with the Securities and Exchange Commission for further information. All public filings, financial statements, management profiles and other Company information are available on the Company’s web site, www.Alzamend.com™.

About Alzamend Neuro™, Inc.

Alzamend Neuro™, Inc. is a Delaware corporation with its corporate headquarters in the State of Florida. The mission of Alzamend Neuro™ is to support the full product development life cycle of treatment and cures for Alzheimer’s driven by the belief that strong support of research is the foundation for true innovation. The Company is providing current hope through the commercialization of existing patented intellectual property and know-how while simultaneously funding future hope through advanced research and development. Alzamend Neuro’s™ underlying goal is to get a treatment or cure for Alzheimer’s to market at a reasonable cost as quickly as possible. Far too many suffer daily, patients and caretakers alike, from the burden created by the nation’s 6th leading cause of death and ‘most feared disease’.

The vision of Alzamend Neuro™ has been to license CAO22W®, the patented mutant peptide for use in immunotherapy and LiProSal, a lithium-based ionic cocrystal oral therapy for patients that have long suffered with the effects of AD from the University of South Florida. There are no profound treatments today for Alzheimer’s. With CAO22W® and LiProSal™, the Company is very hopeful that Alzamend™ can change that. It is one of the Company’s strategic goals to support the continuing research by the teams at the USF Health Byrd Alzheimer’s Institute and other USF Health Colleges to develop and commercialize their results into meaningful solutions.

From his family’s personal experience with relatives having been afflicted with AD, Mr. Milton “Todd” Ault, III, the Company’s Founder and Executive Chairman, diligently studied the status of treatments and the landscape of medical technology. Mr. Ault selected USF and its formative intellectual property and formed Alzamend Neuro™. With over twenty-seven years of experience on Wall Street as an activist driven by his relentless passion for business and technology, Mr. Ault’s efforts have culminated in a commitment to depart from the traditional while forging ahead with an innovative, yet disruptive path to financing the commercialization and the discovery of future solutions.

Forward-looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and those statements are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The Company cautions that these forward-looking statements are further qualified by other factors. The Company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.

Contacts

General Inquiries: Info@Alzamend.com

Investor Inquiries: IR@Alzamend.com

Company Website: www.Alzamend.com

Facebook: https://www.facebook.com/AlzamendNeuro/

Twitter: https://twitter.com/AlzamendNeuro

Instagram: https://www.instagram.com/alzamendneuro/

Pinterest: https://www.pinterest.com/AlzamendNeuroInc/

leverton

I have been involved with publishing and marketing for the past 37 years. My passion is helping people share their voice. I am able to do this through two important venues: One, with Area-Info.net where people can share everything from opinions to events to news. It is your choice! What do you want to share? Two, through a new program called America's Real Deal I am involved with to help business owners get their voice heard.For people who love to save money and earn while saving, there is a new program called the r network. You are provided with a card that entitles the user to automatic savings on more than 300,000 products. Learn more about the revv card today. This is by invitation only to be some of the first people to get this card.I schedule speaking engagements with community groups and business groups to share my passion about the importance of "sharing your voice".Contact me directly at lee@leeeverton.com for scheduling information.

You May Also Like